Skip to content

Metabolic Effect of High-protein Meals in Men

Acute Metabolic Effect of the Protein Quality of a High-protein Meal Replacement in Healthy Men

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00712010
Acronym
OPTI-PROT
Enrollment
25
Registered
2008-07-09
Start date
2008-07-31
Completion date
2011-04-30
Last updated
2013-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Glucose, Insulin

Brief summary

The purpose of the clinical study is to investigate the effect of the protein quality of high-protein meal replacements on the management of post-prandial blood glucose in healthy men.

Detailed description

It was a double-blind, single center, randomized, crossover adaptive study design with 7 arms. The subjects were submitted to 7 tests of ingestion of a high-protein meal replacement (test meal) in randomized order preferably a week apart. The 7 test meals were isocaloric, isonitrogenous and differed in their protein quality.

Interventions

OTHERWhey protein native

Whey protein native against the 6 other arms

OTHERWhey protein microgels

Whey protein microgels versus the six other arms

OTHERHydrolyzed whey protein

versus the six other arms

OTHERCasein native

versus the six other arms

versus the six other arms

OTHERTotal milk protein native

versus the six other arms

OTHERHydrolyzed milk protein

versus the six other arms

Sponsors

Société des Produits Nestlé (SPN)
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
20 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* 20 - 50 years, male * Healthy as determined by a medical questionnaire * Normal weight: BMI 20 - 24.9 kg.m-2 * Normal fasting glycemia and insulinemia * Normal fasting lipidemia (cholesterol and triglycerides) * Normal liver function (transaminases, γ-GT) and kidney function (urea, creatinine) * Capable of fast ingestion of the meal replacement (5-10 min) * Having signed informed consent

Exclusion criteria

* Intestinal or metabolic diseases/disorders such as diabetic, renal, dyslipidemia, hepatic, hypertension, pancreatic or ulcer, including lacto-intolerance. * Hypertension \>150/95 mmHg * Have had a gastrointestinal surgery * Have a regular consumption of medication * Vegetarian, vegan, under dietary supplements * Have an alcohol intake: \> 2 units a day or smoker * Currently participating or having participated in a clinical trial during the last month * Having given blood in the last month * More than 5 x 45 min of intense exercise per week * Volunteer who cannot be expected to comply with treatment

Design outcomes

Primary

MeasureTime frameDescription
Post-prandial Plasma Responses of Glucose Concentrations180 minutesThe concentrations of glucose were analyzed in the 10 plasma samples collected over 3 h postprandially in all subjects (Baseline, 10, 20, 30, 45, 60, 90, 120, 150, and 180 min after product intake). The Area-Under-the-Curves (AUC) over 180 minutes from baseline were calculated by trapezoidal interpolation by excluding the area under baseline.
Calculation of the Area Under Curve Over Baseline for Plasma Insulin180 minutes from baselineThe concentrations of insulin were analyzed in the 10 plasma samples collected over 3 h postprandially in all subjects (Baseline, 10, 20, 30, 45, 60, 90, 120, 150, and 180 min after product intake). The Area-Under-the-Curves (AUC) over 180 minutes from baseline were calculated by trapezoidal interpolation by excluding the area under baseline.

Secondary

MeasureTime frame
Post-prandial Plasma Responses of Glucagon, C-peptide, Amino Acids and Lipids180 minutes

Countries

Switzerland

Participant flow

Recruitment details

Participants were recruited among the Nestlé Research Center staff from June 2008 to May 2009

Pre-assignment details

25 healthy males were recruited; All presented all the inclusion criteria and none of the exclusion criteria listed in the protocol. The day before each test meal, the volunteers were recommended to eat normally as well as to conduct a normal physical activity. A standardized dinner was provided the night before testing.

Participants by arm

ArmCount
Entire Study Population
Includes groups randomized to receive 7 products in a randomized series
25
Total25

Withdrawals & dropouts

PeriodReasonFG000
Washout (7 Days)Withdrawal by Subject1

Baseline characteristics

CharacteristicEntire Study Population
Age Continuous28.3 Years
STANDARD_DEVIATION 1.5
Age, Customized
<=20 years
0 participants
Age, Customized
>=50 years
0 participants
Age, Customized
Between 20 and 50 years
25 participants
Body Mass Index (BMI)23.5 kg/m2
STANDARD_DEVIATION 0.3
Body weight74.2 kg
STANDARD_DEVIATION 1.3
Region of Enrollment
Switzerland
25 participants
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
25 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
EG006
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —— / —— / —— / —— / —
other
Total, other adverse events
0 / 240 / 240 / 230 / 240 / 240 / 230 / 23
serious
Total, serious adverse events
0 / 240 / 240 / 230 / 240 / 240 / 230 / 23

Outcome results

Primary

Calculation of the Area Under Curve Over Baseline for Plasma Insulin

The concentrations of insulin were analyzed in the 10 plasma samples collected over 3 h postprandially in all subjects (Baseline, 10, 20, 30, 45, 60, 90, 120, 150, and 180 min after product intake). The Area-Under-the-Curves (AUC) over 180 minutes from baseline were calculated by trapezoidal interpolation by excluding the area under baseline.

Time frame: 180 minutes from baseline

ArmMeasureValue (MEAN)
Whey Protein NativeCalculation of the Area Under Curve Over Baseline for Plasma Insulin34,428 nmole/L*min
Whey Protein MicrogelsCalculation of the Area Under Curve Over Baseline for Plasma Insulin28,756 nmole/L*min
Hydrolyzed Whey ProteinCalculation of the Area Under Curve Over Baseline for Plasma Insulin32,319 nmole/L*min
Casein NativeCalculation of the Area Under Curve Over Baseline for Plasma Insulin27,082 nmole/L*min
Hydrolyzed CaseinCalculation of the Area Under Curve Over Baseline for Plasma Insulin34,847 nmole/L*min
Total Milk Protein NativeCalculation of the Area Under Curve Over Baseline for Plasma Insulin26,476 nmole/L*min
Hydrolyzed Milk ProteinCalculation of the Area Under Curve Over Baseline for Plasma Insulin37,922 nmole/L*min
Primary

Post-prandial Plasma Responses of Glucose Concentrations

The concentrations of glucose were analyzed in the 10 plasma samples collected over 3 h postprandially in all subjects (Baseline, 10, 20, 30, 45, 60, 90, 120, 150, and 180 min after product intake). The Area-Under-the-Curves (AUC) over 180 minutes from baseline were calculated by trapezoidal interpolation by excluding the area under baseline.

Time frame: 180 minutes

Population: 23 subjects were investigated for AUC of glucose calculations

ArmMeasureValue (MEAN)Dispersion
Whey Protein NativePost-prandial Plasma Responses of Glucose Concentrations136.5 mmole/L*minStandard Error 19
Whey Protein MicrogelsPost-prandial Plasma Responses of Glucose Concentrations121.2 mmole/L*minStandard Error 13.1
Hydrolyzed Whey ProteinPost-prandial Plasma Responses of Glucose Concentrations102.9 mmole/L*minStandard Error 25.4
Casein NativePost-prandial Plasma Responses of Glucose Concentrations160.3 mmole/L*minStandard Error 18.6
Hydrolyzed CaseinPost-prandial Plasma Responses of Glucose Concentrations88.7 mmole/L*minStandard Error 22.3
Total Milk Protein NativePost-prandial Plasma Responses of Glucose Concentrations117.7 mmole/L*minStandard Error 15.6
Hydrolyzed Milk ProteinPost-prandial Plasma Responses of Glucose Concentrations121.5 mmole/L*minStandard Error 19.9
Secondary

Post-prandial Plasma Responses of Glucagon, C-peptide, Amino Acids and Lipids

Time frame: 180 minutes

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026